Until today, the immunohistochemical status of estrogen receptor alpha (ERα), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) has been widely used as a diagnostic tool, based on which the therapy for breast cancer is determined. The gene discussed is ERBB2; the disease is breast carcinoma.